Through the primary screen and subsequent secondary assays, we have discovered that the druggable targets ALK5, MEK, SRC and to some extent PI3K may play a more significant role in EMT modulation and cancer progression, as their associated targeted compounds are inhibitory to several EMT-inducing growth factors (Table 1). Here, MAP2K7 is linked to cancer.